Abstract

EVALUATION OF SAFETY PROFILE AND CLINICAL OUTCOMES OF DESIDUSTAT IN CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY

*Kaveri Jada, Anee Angeleena M., Misbha Fathima, Euvani Yelumala, Dr. Srinivas Nimmagadda and Dr. Mohd. Shoeb Ahmed Khan

Abstract

Background: Chronic Kidney Disease patients develop anemia in the later stages of the disease. We evaluated the efficacy of Desidustat in improving anemia in these patients Materials & Methods: We conducted a prospective analysis of data from patients with chronic kidney disease and anemia who were referred to our department between February 2024 and August 2024, using Desidustat. Results: 200 patients (55.23 ± 15.6 years, 58% males, 42% female) were analyzed. Common presenting symptoms were shortness of breath (63.5% n=127), edema (36.5% n=73), and headache (22.5% n=45). A total of 9(4.5%) patients had stage 3a chronic kidney disease, 21(10.5%) had stage 3b, 94(47%) had stage 4, 76(38%) had stage 5. All the patients were followed up for 4 months. We checked the mean and median difference in all the parameters (Hemoglobin, Serum Creatinine, Blood Urea Nitrogen, Serum Uric acid, Serum Iron, and Serum electrolytes). After follow-up, mean hemoglobin was improved to 11.23 ± 1.02 mg/dL, Serum Creatinine decreased to 0.95 ± 0.21mg/dL, and Blood Urea Nitrogen decreased to 15.384.71mg/dL, Serum Uric acid decreased to 5.57 ± 1.22mg/dL, and Serum Iron improved to 75.03 ± 5.54μg/dL, and all the electrolytes has shown better improvement. Upon follow-up, we observed that all patients experienced a positive impact from Desidustat, which improved their anemic conditions. Conclusion: The current study demonstrates that Desidustat effectively enhances anemia treatment in Chronic Kidney Disease (CKD) patients, significantly raising their hemoglobin levels. Conclusion: Our study demonstrates that Desidustat effectively improves anemia in patients with chronic kidney disease. Over a four-month follow-up period, Desidustat significantly increased hemoglobin levels while contributing to improvements in renal function markers, including reductions in serum creatinine, blood urea nitrogen, and serum uric acid. Additionally, serum iron levels and electrolyte balance showed positive trends. These findings suggest that Desidustat is a promising therapeutic option for managing anemia in CKD patients, potentially enhancing their overall clinical outcomes. Further research with larger sample sizes and longer follow-up periods is recommended to confirm these benefits.

Keywords: Chronic Kidney Disease, Anemia, Desidustat, Hemoglobin.